ID: h-ee1df336
Hypothesis
Vagal Afferent Microbial Signal Modulation
Specific commensal bacteria activate vagal afferent neurons through GLP-1 receptor signaling, promoting neuroprotective pathways in the brainstem and substantia nigra.
EvidencePending (0%)📖 26 cit🗣 1 debates✓ 5 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Specific commensal bacteria activate vagal afferent neurons through GLP-1 receptor signaling, promoting neuroprotective pathways in the brainstem and substantia nigra. Targeted vagal stimulation combined with GLP-1 receptor agonists could enhance endogenous neuroprotection.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
graph TD
A["Commensal Bacteria<br/>Akkermansia and Lactobacillus"] --> B["SCFA Production<br/>Butyrate and Propionate"]
A --> C["Specialized Metabolites<br/>Indole-3-propionic acid and GABA precursors"]
B --> D["Intestinal Epithelium<br/>Metabolite Transport"]
C --> D
D --> E["Enteroendocrine L-cells<br/>Activation"]
E --> F["GLP-1 Release<br/>Incretin Hormone"]
F --> G["Vagal Afferent GLP1R<br/>Receptor Binding"]
G --> H["cAMP Signaling<br/>G-protein Activation"]
H --> I["Vagal Nerve<br/>Signal Transmission"]
I --> J["Brainstem Integration<br/>Nucleus Tractus Solitarius"]
J --> K["Neuroinflammation Reduction<br/>Anti-inflammatory Response"]
J --> L["Neuroprotection<br/>Synaptic Plasticity"]
K --> M["Disease Endpoint<br/>Reduced Neurodegeneration"]
L --> M
N["Therapeutic Intervention<br/>Probiotic Supplementation"] --> A
O["GLP-1 Receptor Agonists<br/>Pharmacological Target"] --> G
style N fill:#e1f5fe,color:#0d0d1a
style O fill:#e1f5fe,color:#0d0d1a
style M fill:#ffebee,color:#0d0d1a⚖️ Evidence
⚖️ Evidence Matrix5 supports2 contradicts
Supports
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.
Supports
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1.
Supports
Brainstem BDNF neurons are downstream of GFRAL/GLP1R signalling.
Supports
Association of semaglutide with risk of suicidal ideation in a real-world cohort.
Contradicts
A phase 3 exenatide Parkinson trial tested GLP-1 receptor agonism as disease modification, providing a direct translational stress test for GLP-1 neuroprotection.
Contradicts
A Cochrane review found the clinical evidence base for GLP-1 receptor agonists in Parkinson disease was limited, cautioning against strong efficacy claims.
📖 Linked Papers (19)Export BibTeX ↗
Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence.
International journal of molecular sciences (2019) · PubMed:31261624 ↗
1 figure
Figure 1
The pathogenesis of new-onset diabetes after transplantation (NODAT). Smaller arrows indicate increase (upward) and decrease (downward). Larger arrows indicate ...
Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
European journal of medicinal chemistry (2019) · PubMed:30877973 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Th17 cells, pathogenic or not? TGF-β3 imposes the embargo
Cellular & Molecular Immunology (2013) · PubMed:23396473 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy.
The Journal of neuroscience : the official journal of the Society for Neuroscience (2005) · PubMed:16079410 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
The microbiome and eating disorders: a new framework at the interface of interoception and reward.
Neuroscience (2026) · PubMed:41921818 ↗
No figures
Brainstem BDNF neurons are downstream of GFRAL/GLP1R signalling.
Nature communications (2024) · PubMed:39737892 ↗
No figures
The potential role of Tirzepatide as adjuvant therapy in countering colistin-induced nephro and neurotoxicity in rats via modulation of PI3K/p-Akt/GSK3-β/NF-kB p65 hub, shielding against oxidative and endoplasmic reticulum stress, and activation of p-CREB/BDNF/TrkB cascade.
International immunopharmacology (2024) · PubMed:38788447 ↗
No figures
The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2024) · PubMed:38518602 ↗
No figures
📙 Related Wiki Pages (15)
Neurofilament Light Chain (NF-L)proteinNEFL GenegeneNeurofilament Light Chain (NfL) in BloodbiomarkerNeurofilament Light Chain (NfL) - BiomarbiomarkerNES ProteinproteinBrain-Derived Neurotrophic Factor (BDNF)proteinBDNF GenegeneMDS 2026 — Fluid Biomarker Advances in NeventGlutamate - Excitotoxicity and NeurodegebiomarkerNeuroimaging Biomarkers for NeurodegenerbiomarkerExosomal Biomarkers in NeurodegenerationbiomarkerCell-Free DNA Biomarkers in NeurodegenerbiomarkerLiquid Biopsy in NeurodegenerationbiomarkerIL-6 (Interleukin-6) in NeurodegeneratiobiomarkerDNA Methylation Biomarkers in Neurodegenbiomarker
🏥 Translation
🧬 3D Protein Structure — GLP1R
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for GLP1R, BDNF from GTEx v10.
💉 Clinical Trials (5)Relevance: 44%
0
Active
Active
0
Completed
Completed
282
Total Enrolled
Total Enrolled
PHASE1
Highest Phase
Highest Phase
RAPA-501 Therapy for ALSPHASE2
RECRUITING·NCT04220190 · Rapa Therapeutics LLC
41 enrolled · 2025-01-02 · → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral Sclerosis
RAPA-501 Autologous T stem cells
COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold
24 enrolled · 2018-12-12 · → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer Dementia Alzheimer Disease
Contraloid
UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center
60 enrolled · 2021-10-01 · → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's DiseasePHASE1
NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.
12 enrolled · 2026-02-28 · → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson Disease
ALC01 therapy
COMPLETED·NCT02405182 · University of Alberta
145 enrolled · 2014-09 · → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases
Magnetic Resonance Imaging
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for GLP1R, BDNF.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
2.0 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 2.9%
Volatility
Medium
0.0354
Events (7d)
5
Price History
▼21.3%💾 Resource Usage
LLM Tokens
34,972
$0.2158
Total Cost
$0.2158
🔮 Predictions
🔎 Predictions vs Observations3 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If hypothesis is true, intervention emphasize superior disease-modifying potential versus purely symptomatic benefits | emphasize superior disease-modifying potential versus purely symptomatic benefits | — no observation — | pending | 0.70 |
| If hypothesis is true, intervention provide personalized dosing recommendations and early detection of treatment response or adverse events | provide personalized dosing recommendations and early detection of treatment response or adverse events | — no observation — | pending | 0.70 |
| If hypothesis is true, intervention maintain GLP1R occupancy above 80% throughout the dosing interval | maintain GLP1R occupancy above 80% throughout the dosing interval | — no observation — | pending | 0.70 |
🔮 Falsifiable Predictions (3)
pendingconf 70%
If hypothesis is true, intervention maintain GLP1R occupancy above 80% throughout the dosing interval
Predicted outcome: maintain GLP1R occupancy above 80% throughout the dosing interval
Falsification: Intervention fails to maintain GLP1R occupancy above 80% throughout the dosing interval
pendingconf 70%
If hypothesis is true, intervention emphasize superior disease-modifying potential versus purely symptomatic benefits
Predicted outcome: emphasize superior disease-modifying potential versus purely symptomatic benefits
Falsification: Intervention fails to emphasize superior disease-modifying potential versus purely symptomatic benefits
pendingconf 70%
If hypothesis is true, intervention provide personalized dosing recommendations and early detection of treatment response or adverse events
Predicted outcome: provide personalized dosing recommendations and early detection of treatment response or adverse events
Falsification: Intervention fails to provide personalized dosing recommendations and early detection of treatment response or adverse events
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.